Bibliography
1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.
2. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the Management of Drug–Drug Interactions Between the COVID ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications . Clin Pharmacol Ther. 2022;0(0):1–10.
3. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90(5):666–73.
4. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20(7):1800–8.
5. Hiremath S, McGuinty M, Argyropoulos C, Brimble KS, Brown P, Chagla Z, et al. Prescribing Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 in Advanced Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022.
6. Richard V, Solas C. Management of drug-drug interactions with nirmatrelvir / ritonavir in patients treated for Covid-19 : Guidelines from the French ( SFPT ). 2020;(January).
7. Lange NW, Salerno DM, Jennings DL, Choe J, Hedvat J, Kovac D, et al. Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant. 2022.
8. Salerno DM, Jennings DL, Lange NW, Kovac D, Shertel T, Chen JK, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022.
Figure 1: Evolution of tacrolimus blood concentration and its dosing regime.
Figure 2: Evolution of serum creatinine.